



FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: STONYB-04970	Serial No.: 09/782,378
INFORMATIONAL DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: Patrick Hearing <i>et al.</i>	
(37 CFR § 1.98(b))		Filing Date:	Group Art Unit: 1636

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
AA2 ↓	1	6,040,174	3/21/00	Imler <i>et al.</i>	X	X	
	2	5,872,005	2/16/99	Wang <i>et al.</i>			
	3	5,837,484	11/17/98	Trempe			
	4	5,589,377	12/31/96	Lebkowski <i>et al.</i>			
	5	5,789,390	8/4/98	Descamps <i>et al.</i>			
	6	5,691,176	11/25/97	Lebkowski <i>et al.</i>			
	7	4,683,195	7/28/87	Mullis <i>et al.</i>			
	8	4,683,202	7/28/87	Mullis			
	9	5,877,011	3/2/99	Armentano <i>et al.</i>			
	10	5,891,690	4/6/99	Massie			

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
AA2 ↓	11	WO 91/18088	11/28/91	PCT	X	X		
	12	WO 90/09441	8/23/90	PCT				
	13	WO 88/10311	12/29/88	PCT				
	14	WO 91/11525	8/8/91	PCT				
	15	WO 99/53085	10/21/99	PCT				
	16	EP 185 573	5/20/92	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AA2 ↓	17	Benihoud <i>et al.</i> (1999) "Adenovirus vectors for gene delivery," Curr. Opin. Biotechnol. 10:440-7
	18	Brenner (1999) "Gene Transfer by Adenovectors," Blood 94:3965-7
	19	Kochanek (1999) "High-Capacity Adenoviral Vectors for Gene Transfer and Somatic Gene Therapy," Hum. Gene. Ther. 10:2451-9
	20	Wold (1999) "Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic," Human Press, Totowa, NJ
	21	Tripathy <i>et al.</i> (1996) "Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors," Nat. Med. 2:545-50
	22	Yang <i>et al.</i> (1996) "Role of Viral Antigens in Destructive Cellular Immune Responses to Adenovirus Vector-Transduced Cells in Mouse Lung," J. Virol. 70:7209-12
	23	Thrasher <i>et al.</i> (1995) "Generation of recombinant adeno-associated virus (rAAV) from an adenoviral vector and functional reconstitution of the NADPH-oxidase," Gene Ther. 2:481-485
	24	Fisher <i>et al.</i> (1996) "A Novel Adenovirus-Adeno-Associated Virus Hybrid Vector That Displays Efficient Rescue and Delivery of the AAV Genome," Human Gene Ther. 7:2079-2087
	25	Lieber <i>et al.</i> (1999) "Integrating Adenovirus-Adeno-Associated Virus Vectors Devoid of All Viral Genes," J. Virol. 73:9314-9324
	26	Liu <i>et al.</i> (1999) "Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus," Gene Ther. 6:293-299

Examiner: <i>Donald A. Lipp</i>	Date Considered: 10-21-02
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: STONYB-04970	Serial No.: 09/782,378
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets if Necessary)				Applicant: Patrick Hearing <i>et al.</i>	
				Filing Date: 2/12/01	Group Art Unit: 1636
(37 CFR § 1.98(b))					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
27	Berns <i>et al.</i> (1995) "Adenovirus and Adeno-Associated Virus as Vectors for Gene Therapy," Ann. NY Acad. Sci. 772:95-104				
28	Muzyczka (1992) "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells," Curr. Top. Microbiol. Immunol. 158:97-129				
29	Rolling and Samulski (1995) Mol. Biotechnol. 3:9-15				
30	Bett <i>et al.</i> (1993) "Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors," J. Virol. 67:5911-21				
31	Parks and Graham (1997) "A Helper-Dependent System for Adenovirus Vector Production Helps Define a Lower Limit for Efficient DNA Packaging," J. Virol. 71:3293-8				
32	Akli <i>et al.</i> (1993) "Transfer of a foreign gene into the brain using adenovirus vectors," Nature Genetics 3:224				
33	Stratford-Perricaudet <i>et al.</i> (1990) "Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector," Human Gene Ther. 1:241				
34	Levero <i>et al.</i> (1991) "Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo," Gene 101:195				
35	Le Gal la Salle <i>et al.</i> (1993) "An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain," Science 259:988				
36	Roemer and Friedmann (1992) "Concepts and strategies for human gene therapy," Eur. J. Biochem. 208:211				
37	Dobson <i>et al.</i> (1990) "A Latent, Nonpathogenic HSV-1-Derived Vector Stably Expresses β -Galactosidase in Mouse Neurons," Neuron 5:353				
38	Chiocca <i>et al.</i> (1990) "Transfer and Expression of the <i>lacZ</i> Gene in Rat Brain Neurons Mediated by Herpes Simplex Virus Mutants," New Biol. 2:739				
39	Miyanojara <i>et al.</i> (1992) "Direct Gene Transfer to the Liver with Herpes Simplex Virus Type 1 Vectors," Transient Production of Physiologically Relevant Levels of Circulating Factor IX," New Biol. 4:238				
40	Xiao <i>et al.</i> (1997) "A Novel 165-Base-Pair Terminal Repeat Sequence Is the Sole <i>cis</i> Requirement for the Adeno-Associated Virus Life Cycle," J. Virol. 71:941-948				
41	Ryan <i>et al.</i> (1996) "Sequence Requirements for Binding of Rep68 to the Adeno-Associated Virus Terminal Repeats," J. Virol. 70:1542-1553				
42	Imler <i>et al.</i> (1996) "Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E-1 deleted adenovirus vectors," Gene Ther. 3:75-84				
43	Fallaux <i>et al.</i> (1998) "New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses," Human Gene Ther. 9:1909-1917				
44	Fallaux <i>et al.</i> (1996) "Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors," Human Gene Ther. 7:215-222				
45	Weinberg <i>et al.</i> (1983) "A cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus type 2," Proc. Natl. Acad. Sci. USA 80:5383-5386				
46	Brough <i>et al.</i> (1996) "A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4," J. Virol. 70:6497-501				
47	Hearing <i>et al.</i> (1987) "Identification of a Repeated Sequence Element Required for Efficient Encapsidation of the Adenovirus Type 5 Chromosome," J. Virol. 61:2555-8				
48	Zolotukhin <i>et al.</i> (1996) "A 'Humanized' Green Fluorescent Protein cDNA Adapted for High-Level Expression in Mammalian Cells," J. Virol. 70:4646-54				
49	Stow (1981) "Cloning of a DNA Fragment from the Left-Hand Terminus of the Adenovirus Type 2 Genome and Its Use in Site-Directed Mutagenesis," J. Virol. 37:171-180				
50	Graham <i>et al.</i> (1977) "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5," J. Gen. Virol. 36:59-74				
51	Thimmappaya <i>et al.</i> (1982) "Adenovirus VAI RNA Is Required for Efficient Translation of Viral mRNAs at Late Times after Infection," Cell, Dec. 31 (3 Pt 2): 543-551				
52	Tollefson <i>et al.</i> (1996) "The Adenovirus Death Protein (E3-11.6K) Is Required at Very Late Stages of Infection for Efficient Cell Lysis and Release of Adenovirus from Infected Cells," J. Virol. 70(4):2296-2306				
Examiner: <i>Donald R. Helff</i>				Date Considered: 10-21-02	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney Docket No.: STONYB-
04970

Serial No.: 09/782,088

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

Applicant: Patrick Hearing *et al.*

Filing Date: 2/12/01

Group Art U

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AA2	53	Steinwaerder <i>et al.</i> (1999) "Generation of Adenovirus Vectors Devoid of All Viral Genes by Recombination between Inverted Repeats," J. Virol. 73:9303-13
	54	Clark <i>et al.</i> (1996) "A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors," Gene Ther. 3:1124-32
	55	Hirt (1967) "Selective Extraction of Polyoma DNA from Infected Mouse Cell Cultures," J. Mol. Biol. 26:365-9
	56	Nevins (1981) "Mechanism of Activation of Early Viral Transcription by the Adenovirus E1A Gene Product," Cell 26:213-20
	57	Sandalon <i>et al.</i> (1997) "In Vitro Assembly of SV40 Virions and Pseudovirions: Vector Development for Gene Therapy," Hum. Gene Ther. 8:843-9
	58	Gnatenko <i>et al.</i> (1999) "An Adenovirus/Adeno-associated Hybrid Virus Generates a Mini-Adenovirus Devoid of all Viral Genes," Blood (supplement) 94:181a, Abstract No. 788
	59	Molin <i>et al.</i> (1998) "Two Novel Adenovirus Vector Systems Permitting Regulated Protein Expression in Gene Transfer Experiments," J. Virol. 72:8358-8361
↓	60	Recchia <i>et al.</i> (1999) "Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector," Proc. Natl. Acad. Sci. USA 96:2615-2620
AA2	61	Sandalon <i>et al.</i> (2000) "AAV Rep Protein Enhances the Generation of a Recombinant Mini-Adenovirus Utilizing an Ad/AAV Hybrid Virus," J. Virol. 74:10381-9

Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.